216 related articles for article (PubMed ID: 14550503)
1. A glance at adenosine receptors: novel target for antitumor therapy.
Merighi S; Mirandola P; Varani K; Gessi S; Leung E; Baraldi PG; Tabrizi MA; Borea PA
Pharmacol Ther; 2003 Oct; 100(1):31-48. PubMed ID: 14550503
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.
Ohana G; Bar-Yehuda S; Barer F; Fishman P
J Cell Physiol; 2001 Jan; 186(1):19-23. PubMed ID: 11147810
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives.
Bahreyni A; Khazaei M; Rajabian M; Ryzhikov M; Avan A; Hassanian SM
J Pharm Pharmacol; 2018 Feb; 70(2):191-196. PubMed ID: 29057476
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of Adenosine Receptors: The State of the Art.
Borea PA; Gessi S; Merighi S; Vincenzi F; Varani K
Physiol Rev; 2018 Jul; 98(3):1591-1625. PubMed ID: 29848236
[TBL] [Abstract][Full Text] [Related]
5. Vascular adenosine receptors; potential clinical applications.
Ho MF; Rose'Meyer RB
Curr Vasc Pharmacol; 2013 May; 11(3):327-37. PubMed ID: 22724462
[TBL] [Abstract][Full Text] [Related]
6. Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment.
Chiarella AM; Ryu YK; Manji GA; Rustgi AK
Trends Cancer; 2021 Aug; 7(8):731-750. PubMed ID: 34074623
[TBL] [Abstract][Full Text] [Related]
7. Adenosine receptors and cancer.
Gessi S; Merighi S; Sacchetto V; Simioni C; Borea PA
Biochim Biophys Acta; 2011 May; 1808(5):1400-12. PubMed ID: 20888788
[TBL] [Abstract][Full Text] [Related]
8. Purinergic signalling in brain ischemia.
Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
[TBL] [Abstract][Full Text] [Related]
9. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines.
Morrone FB; Jacques-Silva MC; Horn AP; Bernardi A; Schwartsmann G; Rodnight R; Lenz G
J Neurooncol; 2003 Sep; 64(3):211-8. PubMed ID: 14558596
[TBL] [Abstract][Full Text] [Related]
10. Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures.
Neary JT; McCarthy M; Kang Y; Zuniga S
Neurosci Lett; 1998 Feb; 242(3):159-62. PubMed ID: 9530930
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives.
Soleimani A; Bahreyni A; Roshan MK; Soltani A; Ryzhikov M; Shafiee M; Soukhtanloo M; Jaafari MR; Mashkani B; Hassanian SM
J Cell Physiol; 2019 Mar; 234(3):2329-2336. PubMed ID: 30191994
[TBL] [Abstract][Full Text] [Related]
12. On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells.
Costa MA; Barbosa A; Neto E; Sá-e-Sousa A; Freitas R; Neves JM; Magalhães-Cardoso T; Ferreirinha F; Correia-de-Sá P
J Cell Physiol; 2011 May; 226(5):1353-66. PubMed ID: 20945394
[TBL] [Abstract][Full Text] [Related]
13. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells.
Hoskin DW; Butler JJ; Drapeau D; Haeryfar SM; Blay J
Int J Cancer; 2002 May; 99(3):386-95. PubMed ID: 11992407
[TBL] [Abstract][Full Text] [Related]
14. Adenosine inhibits tumor cell invasion via receptor-independent mechanisms.
Virtanen SS; Kukkonen-Macchi A; Vainio M; Elima K; Härkönen PL; Jalkanen S; Yegutkin GG
Mol Cancer Res; 2014 Dec; 12(12):1863-74. PubMed ID: 25080434
[TBL] [Abstract][Full Text] [Related]
15. Beneficial and detrimental role of adenosine signaling in diseases and therapy.
Liu H; Xia Y
J Appl Physiol (1985); 2015 Nov; 119(10):1173-82. PubMed ID: 26316513
[TBL] [Abstract][Full Text] [Related]
16. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor.
Fishman P; Bar-Yehuda S; Ohana G; Pathak S; Wasserman L; Barer F; Multani AS
Eur J Cancer; 2000 Jul; 36(11):1452-8. PubMed ID: 10899660
[TBL] [Abstract][Full Text] [Related]
17. Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.
Koszałka P; Gołuńska M; Urban A; Stasiłojć G; Stanisławowski M; Majewski M; Składanowski AC; Bigda J
PLoS One; 2016; 11(3):e0151420. PubMed ID: 26964090
[TBL] [Abstract][Full Text] [Related]
18. Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature.
Sousa JB; Fresco P; Diniz C; Goncalves J
Recent Pat Anticancer Drug Discov; 2018; 13(1):40-69. PubMed ID: 29119938
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of adenosine receptors in the vasculature.
Tabrizchi R; Bedi S
Pharmacol Ther; 2001 Aug; 91(2):133-47. PubMed ID: 11728606
[TBL] [Abstract][Full Text] [Related]
20. Adenosine pathway and cancer: where do we go from here?
Antonioli L; Haskó G; Fornai M; Colucci R; Blandizzi C
Expert Opin Ther Targets; 2014 Sep; 18(9):973-7. PubMed ID: 24958495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
